Ritholtz Wealth Management Has $203,000 Position in Moderna, Inc. (NASDAQ:MRNA)

Posted by Defense World Staff on Sep 30th, 2023

Ritholtz Wealth Management raised its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 9.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,670 shares of the company’s stock after buying an additional 145 shares during the period. Ritholtz Wealth Management’s holdings in Moderna were worth $203,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. ICA Group Wealth Management LLC acquired a new position in shares of Moderna during the 4th quarter worth about $27,000. GHP Investment Advisors Inc. increased its stake in shares of Moderna by 208.3% during the 1st quarter. GHP Investment Advisors Inc. now owns 185 shares of the company’s stock worth $28,000 after purchasing an additional 125 shares during the last quarter. Stone House Investment Management LLC acquired a new position in shares of Moderna during the 1st quarter worth about $36,000. Heritage Wealth Management LLC increased its stake in shares of Moderna by 100.0% during the 4th quarter. Heritage Wealth Management LLC now owns 226 shares of the company’s stock worth $41,000 after purchasing an additional 113 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC increased its stake in shares of Moderna by 79.1% during the 1st quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after purchasing an additional 125 shares during the last quarter. 64.51% of the stock is currently owned by institutional investors and hedge funds.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $103.29 on Friday. The firm has a 50 day moving average of $108.34 and a 200-day moving average of $125.34. The stock has a market capitalization of $39.31 billion, a PE ratio of 38.11 and a beta of 1.63. Moderna, Inc. has a 12 month low of $95.02 and a 12 month high of $217.25. The company has a current ratio of 3.39, a quick ratio of 3.16 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($3.62) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.84) by $0.22. The business had revenue of $344.00 million during the quarter, compared to analysts’ expectations of $307.67 million. Moderna had a net margin of 11.33% and a return on equity of 6.62%. The firm’s quarterly revenue was down 92.8% compared to the same quarter last year. During the same period in the prior year, the company earned $5.24 EPS. On average, equities research analysts predict that Moderna, Inc. will post -4.32 EPS for the current fiscal year.

Insider Buying and Selling

In related news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $120.60, for a total transaction of $1,809,000.00. Following the completion of the transaction, the president now directly owns 1,602,303 shares in the company, valued at approximately $193,237,741.80. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $120.60, for a total value of $1,809,000.00. Following the completion of the transaction, the president now directly owns 1,602,303 shares in the company, valued at approximately $193,237,741.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Noubar Afeyan sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 27th. The shares were sold at an average price of $98.96, for a total transaction of $989,600.00. Following the completion of the transaction, the director now owns 2,196,931 shares of the company’s stock, valued at $217,408,291.76. The disclosure for this sale can be found here. Insiders sold a total of 217,054 shares of company stock worth $24,604,198 in the last three months. 15.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. HSBC assumed coverage on shares of Moderna in a report on Friday, July 14th. They set a “reduce” rating and a $97.00 target price for the company. William Blair assumed coverage on shares of Moderna in a report on Monday, July 24th. They set a “market perform” rating and a $136.28 target price for the company. TD Cowen downgraded shares of Moderna from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $145.00 to $125.00 in a report on Friday, August 4th. UBS Group raised shares of Moderna from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $221.00 to $191.00 in a report on Monday, June 26th. Finally, Argus reduced their target price on shares of Moderna from $160.00 to $140.00 and set a “buy” rating for the company in a report on Wednesday, September 13th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $155.52.

Check Out Our Latest Research Report on MRNA

Moderna Company Profile

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.